clinical trial · NCT05177211
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
H. Lee Moffitt Cancer Center and Research Institute·phase2·active not recruiting·n = 25
Myeloproliferative NeoplasmChronic Neutrophilic LeukemiaMDSFedratinib Pill
brief summary
The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL).
started
Mar 1, 2022
primary completion
Apr 10, 2025
completion
Apr 1, 2026
last updated
Apr 17, 2026
official title
A Phase 2 Study of Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol